News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
278,108 Results
Type
Article (14751)
Company Profile (102)
Press Release (263247)
Multimedia
Podcasts (76)
Webinars (14)
Section
Business (88806)
Career Advice (493)
Deals (15494)
Drug Delivery (80)
Drug Development (37023)
Employer Resources (55)
FDA (6447)
Job Trends (6324)
News (151665)
Policy (14181)
Tag
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (453)
Accelerated approval (21)
Adcomms (10)
Allergies (90)
Alliances (23415)
ALS (68)
Alzheimer's disease (516)
Antibody-drug conjugate (ADC) (148)
Approvals (6716)
Artificial intelligence (254)
Autoimmune disease (70)
Automation (19)
Bankruptcy (151)
Best Places to Work (4407)
BIOSECURE Act (10)
Biosimilars (146)
Biotechnology (39)
Bladder cancer (47)
Brain cancer (40)
Breast cancer (196)
Cancer (1613)
Cardiovascular disease (184)
Career advice (437)
Career pathing (15)
CAR-T (62)
CDC (9)
Cell therapy (196)
Cervical cancer (15)
Clinical research (32578)
Collaboration (897)
Company closure (1)
Compensation (375)
Complete response letters (42)
COVID-19 (795)
CRISPR (51)
C-suite (593)
Cystic fibrosis (60)
Data (2285)
Decentralized trials (1)
Denatured (18)
Depression (58)
Dermatology (13)
Diabetes (145)
Diagnostics (1434)
Digital health (13)
Diversity (3)
Diversity, equity & inclusion (16)
Drug discovery (147)
Drug pricing (122)
Drug shortages (15)
Duchenne muscular dystrophy (98)
Earnings (34252)
Editorial (27)
Employer branding (6)
Employer resources (51)
Events (39765)
Executive appointments (596)
FDA (7767)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (2)
Frontotemporal dementia (8)
Funding (515)
Gene editing (82)
Generative AI (24)
Gene therapy (204)
GLP-1 (475)
Government (1441)
Grass and pollen (4)
Guidances (171)
Healthcare (3654)
HIV (16)
Huntington's disease (12)
IgA nephropathy (48)
Immunology and inflammation (91)
Immuno-oncology (24)
Indications (82)
Infectious disease (886)
Inflammatory bowel disease (85)
Inflation Reduction Act (7)
Influenza (28)
Intellectual property (130)
Interviews (63)
IPO (5948)
IRA (33)
Job creations (2074)
Job search strategy (388)
JPM (32)
Kidney cancer (11)
Labor market (38)
Layoffs (224)
Leadership (9)
Legal (3458)
Liver cancer (24)
Longevity (9)
Lung cancer (213)
Lymphoma (146)
Machine learning (14)
Management (18)
Manufacturing (527)
MASH (85)
Medical device (1312)
Medtech (1325)
Mergers & acquisitions (10036)
Metabolic disorders (523)
mRNA (64)
Multiple sclerosis (58)
NASH (15)
Neurodegenerative disease (106)
Neuropsychiatric disorders (48)
Neuroscience (1033)
Neurotech (1)
NextGen: Class of 2026 (1603)
Non-profit (616)
Now hiring (55)
Obesity (272)
Opinion (153)
Ovarian cancer (58)
Pain (133)
Pancreatic cancer (63)
Parkinson's disease (98)
Partnered (12)
Patents (263)
Patient recruitment (161)
Peanut (15)
People (30268)
Pharmaceutical (61)
Pharmacy benefit managers (18)
Phase 1 (8462)
Phase 2 (13751)
Phase 3 (12434)
Pipeline (3062)
Policy (149)
Postmarket research (1404)
Preclinical (3419)
Press Release (25)
Prostate cancer (102)
Psychedelics (20)
Radiopharmaceuticals (153)
Rare diseases (451)
Real estate (2672)
Recruiting (21)
Regulatory (11306)
Reports (17)
Research institute (586)
Resumes & cover letters (61)
Rett syndrome (9)
RNA editing (8)
RSV (24)
Schizophrenia (88)
Series A (105)
Series B (59)
Service/supplier (2)
Sickle cell disease (53)
Special edition (12)
Spinal muscular atrophy (87)
Sponsored (11)
Startups (1660)
State (2)
Stomach cancer (6)
Supply chain (59)
Tariffs (78)
The Weekly (55)
Vaccines (271)
Venture capital (40)
Weight loss (163)
Women's health (44)
Worklife (4)
Date
Last 7 days (336)
Last 30 days (1052)
Last 365 days (10449)
2026 (3949)
2025 (10804)
2024 (12650)
2023 (14420)
2022 (19708)
2021 (20224)
2020 (19124)
2019 (14969)
2018 (11766)
2017 (13959)
2016 (13165)
2015 (15529)
2014 (12446)
2013 (10609)
2012 (11440)
2011 (11948)
2010 (10909)
Location
Africa (324)
Alabama (21)
Alaska (1)
Arizona (83)
Arkansas (4)
Asia (21200)
Australia (2727)
California (3753)
Canada (1707)
China (675)
Colorado (169)
Connecticut (149)
Delaware (152)
Europe (41616)
Florida (699)
Georgia (74)
Hawaii (1)
Idaho (10)
Illinois (437)
India (61)
Indiana (289)
Iowa (2)
Japan (312)
Kansas (80)
Kentucky (21)
Louisiana (6)
Maine (2)
Maryland (483)
Massachusetts (3037)
Michigan (50)
Minnesota (195)
Mississippi (1)
Missouri (37)
Montana (9)
Nebraska (8)
Nevada (18)
New Hampshire (10)
New Jersey (1650)
New Mexico (8)
New York (1074)
North Carolina (709)
North Dakota (2)
Northern California (1749)
Ohio (93)
Oklahoma (5)
Oregon (18)
Pennsylvania (828)
Puerto Rico (17)
Rhode Island (18)
South America (510)
South Carolina (12)
Southern California (1648)
Tennessee (64)
Texas (535)
United States (14826)
Utah (66)
Virginia (196)
Washington D.C. (44)
Washington State (273)
West Virginia (1)
Wisconsin (46)
Wyoming (1)
278,108 Results for "takeda pharmaceutical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Lilly Wakes Up Sleep Market With $6.3B Centessa Buy To Challenge Takeda
In the buyout, Eli Lilly picks up Centessa Pharmaceuticals’ lead asset cleminorexton, which could go toe-to-toe with Takeda’s oveporexton, currently under FDA review with a decision expected in the third quarter.
March 31, 2026
·
2 min read
·
Tristan Manalac
Neurodegenerative diseases
Takeda Breaks Up With Denali, Dumps Dementia Drug
Takeda and Denali Therapeutics first partnered in early 2018 to advance drugs for neurodegenerative diseases. One asset, for Alzheimer’s disease, was previously discontinued after an FDA hold and disappointing early data.
April 6, 2026
·
2 min read
·
Tristan Manalac
Layoffs
Takeda Restructuring Could Push More Than 600 US Staffers Out of Jobs
Takeda’s layoffs include cutting 247 people in Massachusetts. The workforce reduction is meant to help offset investments in areas including a product launch for oral drug candidate zasocitinib, for which the pharma today announced positive Phase 3 data.
March 30, 2026
·
2 min read
·
Angela Gabriel
Business
Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In Silico
After divorcing Denali Therapeutics earlier this month, Takeda is now splitting up with Veritas In Silico, pulling back from a partnership that advanced novel small-molecule drugs targeting mRNA.
April 15, 2026
·
2 min read
·
Tristan Manalac
IN PARTNERSHIP WITH TAKEDA
Takeda’s Commitment to Trial Representation is Shaping the Future of Clinical Research
One way Takeda lives out its values is by striving to ensure that patients are aware of and can access the company’s clinical trials. Two employees from its research and development organization discuss why representation matters and the work their team is doing to benefit patients now and in the future.
January 5, 2026
·
5 min read
·
BioSpace Insights
Immunology and inflammation
Takeda’s $4B Nimbus Bet Pays Off With ‘Best-in-Class’ Phase III Plaque Psoriasis Data
With zasocitinib, Takeda is looking to challenge Bristol Myers Squibb’s kinase inhibitor Sotyktu, for which the Japanese pharma is running a head-to-head study in plaque psoriasis. Takeda expects to file for zasocitinib’s FDA approval next year.
December 19, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
March 30, 2026
·
16 min read
Press Releases
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
April 28, 2026
·
7 min read
Press Releases
Alan Walshe Appointed General Manager of Takeda Canada
March 2, 2026
·
2 min read
Cell therapy
How Takeda Built Its Cell Therapy Portfolio, Only To Walk Away
Takeda wanted to create something new in the cell therapy world by combining the technology with T cell engagers. A series of acquisitions in 2021 started the process.
October 8, 2025
·
2 min read
·
Annalee Armstrong
1 of 27,811
Next
